351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (182)
- Autoimmune Disorders (3)
- Blood Disorders (8)
- Cancer
(111)
- Bladder Cancer (1)
- Brain Cancer (2)
- Breast Cancer (2)
- Gastrointestinal (3)
- Gynecologic Cancer (3)
- Head and Neck Cancer (2)
- Kidney Cancer (3)
- Leukemia (9)
- Liver Cancer (1)
- Lung Cancer (14)
- (-) Lymphoma (8)
- Multiple Myeloma (6)
- Pancreatic Cancer (1)
- Prostate Cancer (9)
- (-) Sarcoma (4)
- Skin Cancer (5)
- Solid Tumors (7)
- Diabetes (1)
- Healthy Volunteers (3)
- Heart Disease (2)
- Infectious Disease (3)
- Neurological Disorders (16)
- Nutrition (1)
- Obstetrics & Gynecology (1)
- Pediatrics (15)
- Psychiatric Disorders (1)
- Transplant (16)
- Urology (1)
Displaying 1 - 12 of 12
Condition: Cancer / Lymphoma
Investigator: Hua-Jay Cherng, MD
Status: Currently Recruiting
Can we lower the chance of Diffuse Large B-cell Lymphoma (DLBCL) cancer growing or spreading by adding treatment to the usual therapy? This study is being done to find out if this approach is better or worse than the usual approach for DLBCL patients receiving chimeric antigen receptor (CAR) T-cell…
Condition: Cancer / Lymphoma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants…
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Currently Recruiting
The purpose of this study is to find out the safety, effectiveness, and blood levels of various doses of the study drug in participants with T-cell lymphoma that has not improved or has gotten worse. ONO-4685 is an experimental drug which is not approved by Health Authorities including the United States Food and Drug…
Condition: Cancer / Lymphoma
Investigator: Markus Mapara, MD
Status: Closed
The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant. An autologous transplant is infusion of your own bone marrow cells (stem cells) following a high-…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
The purpose of this study is to compare the usual treatment alone to using tazemetostat or zanubrutinib plus the usual treatment for patients with relapsed or refractory large B-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment. Refractory means the LBCL did not respond to earlier…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (like people who have had a transplant and must be on medications that suppress their immune sy…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (people who have had a transplant and those who have immune disorders), EBV can cause certain…
Condition: Cancer / Lymphoma
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study will utilize an investigational drug combination (also known as the study drugs) called relatlimab and nivolumab as a possible treatment for recurrent/relapsed (returned) or refractory (treatment-resistant) cHL and NHL. An investigational drug combination is one that has not been approved by regulatory agencies, such as the United States (US)…
Condition: Cancer / Sarcoma
Investigator: Brian Henick, MD
Status: Closed
This research study mainly aims to test the safety and tolerability of AGEN1181 and balstilimab and to determine the most appropriate dose of the study drug AGEN1181 alone and in combination with balstilimab. AGEN1181 targets cells that are a part of the body's immune system to block a protein…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this research study is to determine the effectiveness and safety of envafolimab, an experimental drug that is not approved for use, when given alone or in combination with ipilimumab to stimulate your immune system to attack cancer cells. Envafolimab is an experimental (…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The experimental drug called INBRX 109 has been developed as a treatment for unresectable or metastatic conventional chondrosarcoma. The purpose of this study is to learn about the effects of the study drug, INBRX-109 on you, your immune system, and your cancer. This study is being done to understand if INBRX-109 is effective…
Condition: Cancer / Sarcoma
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to: 1. Compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone. 2. Evaluate the effect of nivolumab in combination with cabozantinib on angiosarcoma (cancer) in…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE